Regeneron
Regeneron Pharmaceuticals, Inc., commonly referred to as Regeneron, is a leading biotechnology company headquartered in the United States. Founded in 1988, Regeneron has established itself as a pioneer in the development of innovative medicines, particularly in the fields of ophthalmology, oncology, and immunology. With a strong focus on research and development, Regeneron is renowned for its unique products, including EYLEA® for eye diseases and Dupixent® for various allergic conditions. The company’s commitment to scientific excellence has positioned it as a key player in the biopharmaceutical industry, achieving significant milestones such as the rapid development of treatments during public health emergencies. Regeneron continues to expand its global footprint, with major operations across North America and Europe, solidifying its reputation as a leader in advancing healthcare solutions.
DitchCarbon Score
How does Regeneron's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Regeneron's score of 35 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Regeneron's reported carbon emissions
In 2023, Regeneron reported total carbon emissions of approximately 972,376,000 kg CO2e. This figure includes Scope 1 emissions of about 69,600,000 kg CO2e, Scope 2 emissions of approximately 29,900,000 kg CO2e (market-based), and significant Scope 3 emissions totalling around 872,876,000 kg CO2e. The Scope 3 emissions are primarily driven by purchased goods and services, which account for about 660,589,000 kg CO2e. Regeneron has demonstrated a commitment to sustainability, although specific reduction targets or initiatives have not been disclosed. The company has reported emissions data across all three scopes (1, 2, and 3) in recent years, indicating a comprehensive approach to tracking its carbon footprint. Overall, Regeneron's emissions reflect its operational scale and the nature of its business, with a focus on addressing climate impact through transparency in reporting.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 39,400,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 25,300,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 288,800,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Regeneron is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
